With the new drug application (NDA) of recombinant human coagulation factor VIII-Fc fusion protein as a trademark, Gensciences is taking a step forward towards our initial goal of providing hemophilia patients with superior “zero bleeding” treatment options. We, the Jiangsu Gensciences Inc. and Gensciences Group, are also transforming ourself from a biotechnological research group to biological pharmaceutical companies.

Based on the clinical needs of patients with hemophilia, the companies are committed to developing innovative biological drugs with clinical advantages, superior safety and efficacy. Our platforms rely on our independently established unique modification technologies. With the research and development focusing on the targets of rare diseases, we are expanding from hemophilia treatment to other indications such as coagulation disorders, forming unique development pipelines.

The developing pipelines of four long-acting/ultra-long-acting recombinant coagulation factor for Gensciences group cover hemophilia A, hemophilia B and hemophilia with inhibitors, and they will be expanded the indications such as acute hemostasis and trauma hemostasis.

The NDA application and the progress in the clinical trials of the four new Class Ⅰ biologics will fill in the lack of commercially available long-acting recombinant coagulation factors in Chinese market and increase the accessibility and adherence to medication the hemophilia patients; meanwhile, the cutting-edge technology will ensure the competitiveness of the products in the global hemophilia treatment field and bring returns to our investors.

We commit to the patients, the science and the society.